Updated · University of Minnesota Twin Cities · Jun 30
AI-Built 3-Protein Coronavirus Vaccine Heads to Trials After 15 Million-Strain Scan
Updated
Updated · University of Minnesota Twin Cities · Jun 30
AI-Built 3-Protein Coronavirus Vaccine Heads to Trials After 15 Million-Strain Scan
1 articles · Updated · University of Minnesota Twin Cities · Jun 30
Summary
Early next year, clinical trials are slated to begin on a long-COVID therapy derived from Lbachir BenMohamed’s AI-enabled broad-spectrum coronavirus vaccine research.
Using machine learning, his team screened 15 million coronavirus strains, found 10 proteins conserved across the family’s 29 proteins, then narrowed the final vaccine design to 3 proteins through animal studies.
BenMohamed said the AI-assisted preclinical process took about 4 years instead of roughly 12, aiming to trigger T-cell responses that could protect against SARS-CoV-2, MERS-CoV and SARS-CoV.
Researchers said AI can speed vaccine discovery and help teams fail faster, but no AI-discovered drugs have yet moved beyond clinical trials and human testing remains essential.
The work points to broader AI use in vaccinology—from flu-strain prediction to trial design—while data-sharing gaps, uneven datasets and public distrust still limit how far the technology can go.
AI-designed vaccines are now succeeding in human trials. What's the biggest hurdle preventing their widespread use?
AI promises to slash vaccine development costs. Will patients actually see any of these savings?
AI-Driven DIOS-CoVax DNA Vaccine Completes Phase 1: Toward Universal Coronavirus and Pandemic Immunity
Overview
The DIOS-CoVax (pEVAC-PS) vaccine, developed by the University of Cambridge and DIOSynVax, is the world’s first AI-designed universal coronavirus vaccine. This DNA-based vaccine uses a needle-free, microfluidic jet injection system that delivers the vaccine through the skin with high-pressure air, making it less uncomfortable than traditional needles. The innovative design not only targets current and future coronavirus variants but can also be adapted for other viruses like Ebola, showing broad potential. These features highlight DIOS-CoVax as a major step forward in vaccine technology, aiming for safer, more effective, and widely accessible protection.